In the coming year, we will complete our pre-surgical window trial (NU-12B09, 2-10 weeks of telapristone 12.5 mg in Stage I-II breast cancer patients); initiate an NCI-funded comparison of oral and transdermal telapristone (CDB4124) in a window setting; and continue preclinical evaluation of CDB-4124 in comparison to classical and additional novel anti-progestins. However, the major focus of the experiments described below will be to generate data to support a Phase II prevention trial using telapristone in BRCA mutation carriers.
|Effective start/end date||10/1/14 → 9/30/16|
- Breast Cancer Research Foundation (Form 08/22/2014)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.